At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 13, 2026 at 16:01 ET
Xenon Pharmaceuticals amended and restated its 2025 Inducement Equity Incentive Plan to increase the share reserve from 900,000 to 1,175,000 common shares, to be used exclusively for hiring inducements. This filing is routine and does not involve any new equity grants or executive appointments.
- Company amended and restated its 2025 Inducement Equity Incentive Plan
- Increased share reserve from 900,000 to 1,175,000 common shares
- New shares to be used exclusively for inducement grants to new hires or rehires
- No shareholder approval required under Nasdaq Listing Rule 5635(c)(4)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access